Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
29 hedge funds and large institutions have $184M invested in Achilles Therapeutics in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 7 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
34% less capital invested
Capital invested by funds: $278M → $184M (-$94.3M)
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$49.2M |
| 2 |
Axa
Paris,
France
|
+$3.65M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.19M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$746K |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$7.81M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7.37M |
| 3 |
DM
Deerfield Management
New York
|
-$6.76M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.19M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$1.31M |
ACHL Hedge Fund Activity: Q2 2021 in Review
29 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2021, worth a combined $184M — down 34% from $278M a quarter earlier.
Fund positioning in ACHL was balanced in Q2 2021: 7 funds opened new positions, 7 closed out, 3 added to existing stakes and 13 trimmed.
The largest buyer was RA Capital Management, adding an estimated $49.2M. The largest seller was JP Morgan Chase, cutting an estimated $7.81M.
- 29 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $184M of Achilles Therapeutics stock for Q2 2021, down 34% quarter-over-quarter.
- 7 funds opened new Achilles Therapeutics positions in Q2 2021 and 7 closed out, a net change of 0 holders.
- The largest Achilles Therapeutics buyer in Q2 2021 was RA Capital Management, an estimated $49.2M added.
- The largest Achilles Therapeutics seller in Q2 2021 was JP Morgan Chase, an estimated $7.81M sold.
Based on aggregated 13F filings for Q2 2021.